PHIL in the Treatment of Intracranial dAVF.

PHIL dAVF: Study of PHIL® Embolic System In The Treatment of Intracranial Dural Arteriovenous Fistulas

This study is a prospective, multicenter, single-arm study. Patients with Dural Arteriovenous Fistulas (dAVF) have a few choice for safe treatment. In this study, all patients with qualifying dAVFs will be treated with PHIL® Liquid Embolic material.

Inclusion Criteria:

• Age 22 - 80 years.
• Subject is willing and capable of complying with all study protocol requirements, including specified follow-up period.
• Subject or authorized legal representative must provide written informed consent prior to initiation of any study procedures.
• Subject has an intracranial dAVF

Exclusion Criteria:

• Subject having multiple dAVFs to be treated.
• Subject with a history of life threatening allergy to contrast media (unless treatment for allergy is tolerated).
• Subject has known allergies to dimethylsulfoxide, iodine.
• Subject is currently participating in another clinical study
• Female subject is currently pregnant.
• Subject has co-morbid conditions that may limit survival to less than 24 months.